Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECOMA study
ChiCTR-IPR-17010829Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Xuezhikang in hypertension (HTN) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Retinal vascular wall thickness, Carotid intima-media thickness and 2 more. Started Dec 2016; status: recruiting.
02
Drugs
Xuezhikang
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR-IPR-17010829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010829.